Overall I am pleased with the way PDN management have dealt with this raising. I suspect retail shareholders are happy to have been included in the 26 entitlement, at a time the U market is looking really positive, rather than the previous 70c CR just before the U price collapse that was only for Institutions...
I did find it strange that retail investors weren't able to subscribe for multiples of their entitlement, since my understanding of the concept of "underwriting" is to act as a backstop for shares that were not in demand.
It looks good however that both retailers and underwriters appear to be fighting over the % of the scraps left on the table.
I remember a year or two ago, when PDN was vulnerable to it's huge debt, John B was heavily criticised on this forum, I'd just like to give him a thumbs up for how he and his team have navigated a tricky couple of years. Hopefully onwards and upwards from here.
- Forums
- ASX - By Stock
- PDN
- Ann: Successful Completion of A$94.6M Retail Entitlement Offer
Ann: Successful Completion of A$94.6M Retail Entitlement Offer, page-31
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PDN (ASX) to my watchlist
|
|||||
Last
$13.66 |
Change
-0.140(1.01%) |
Mkt cap ! $4.072B |
Open | High | Low | Value | Volume |
$13.64 | $13.76 | $13.60 | $2.688M | 197.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
25 | 1784 | $13.66 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.67 | 1163 | 12 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
15 | 1355 | 13.680 |
18 | 3157 | 13.670 |
11 | 3169 | 13.660 |
9 | 2979 | 13.650 |
8 | 3892 | 13.640 |
Price($) | Vol. | No. |
---|---|---|
13.690 | 932 | 10 |
13.700 | 1840 | 13 |
13.710 | 2877 | 12 |
13.720 | 2502 | 11 |
13.730 | 3131 | 8 |
Last trade - 11.49am 16/07/2024 (20 minute delay) ? |
Featured News
PDN (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online